CAR T-Cell Therapy is an extraordinary and innovative cancer treatment paradigm that engineers a patient’s own cells to hunt and attack cancer cells. A personalized, next-generation treatment, CAR T is a new and powerful tool for treating advanced forms of cancer and bringing hope to patients and families.  In this presentation, you’ll hear a little more about how CAR T works and the potential benefit to patients.  Michelle Sharr, our clinical speaker, will present on CAR T and host a Q&A.

SPEAKER:
Michele Sharr, Director of Global Research & Development, Clinical Scientist, Bristol-Myers Squibb Company. She will host a E&A

Michele Sharr is the Director of Global Drug Development with a graduate degree in Biochemistry from the University of Pennsylvania / Drexel Univerity, Philadelphia, PA. She has 28 years of experience in the Pharmaceutical Industry: 12 years in pre-clinical labs developing medicines specific to Immunology (organ transplants, autoimmune diseases, and oncology); 16 years in clinical research leading trials in such indications as Oncology (solid tumors and blood cancers) as well as Cardiovascular and Metabolism in both adult and pediatric patients. She has contributed to 6 drug approvals including the 1st CAR T therapy; an additional 2 drug approvals currently in progress. She was the 1st scientist at Novartis to develop a CAR T program; treated the 1st ever pediatric patient and contributed to the approval of the 1st ever marketed CAR T product (Kymriah). She has authored multiple scientific publications, abstracts, and posters. She is a Political Action Committee Board Member meeting with members of US Congress and State Legislators to provide education regarding pharmaceutical research and the continued need for medical innovation. She is also the manager of multiple direct reports and acts as a mentor to interns and colleagues new to the industry. Her motto is “Lead with Kindness.” On a personal note, Michele has been a cancer patient herself and helps care for both of her parents who currently have 2 different forms of blood cancer. These experiences have heightened her motivation to develop treatments for patients with unmet medical needs.

Click HERE to Register.